title: Effects of the synthetic trypsin inhibitor camostate on the development of N-nitrosobis(2-oxopropyl)amine-induced pancreatic lesions in hamsters.
abstract: Trypsin inhibitors have been shown to promote pancreatic growth as well as the development of pancreatic tumours in rats. The present study was carried out to examine the effects of the synthetic trypsin inhibitor camostate on the growth of the pancreas and on the development of pancreatic preneoplastic and neoplastic lesions in hamsters treated with N-nitrosobis(2-oxopropyl)amine. A specific cholecystokinin-receptor antagonist was administered to determine the role of cholecystokinin in camostate action. The animals were killed 19 weeks after the first injection with N-nitrosobis(2-oxopropyl)amine. Camostate caused an increase in growth of the pancreas and a decrease in the number of (pre)neoplastic ductular pancreatic lesions. Lorglumide (CR-1409) did not influence these effects of camostate. It was concluded that rats and hamsters behave differently with regard to the effect of camostate on pancreatic growth and carcinogenesis.
authors.affiliation: Department of Biological Toxicology, TNO Toxicology and Nutrition Institute, Zeist, The Netherlands.
authors.forename: M
authors.initials: M
authors.lastname: Meijers
authors.forename: A
authors.initials: A
authors.lastname: van Garderen-Hoetmer
authors.forename: C B
authors.initials: CB
authors.lastname: Lamers
authors.forename: L C
authors.initials: LC
authors.lastname: Rovati
authors.forename: J B
authors.initials: JB
authors.lastname: Jansen
authors.forename: R A
authors.initials: RA
authors.lastname: Woutersen
mesh_terms: D000818:Animals; D002273:Carcinogens / Q000633:toxicity*; D002277:Carcinoma / Q000139:chemically induced* / Q000473:pathology; D002278:Carcinoma in Situ / Q000139:chemically induced* / Q000473:pathology; D002766:Cholecystokinin / Q000037:antagonists & inhibitors; D006224:Cricetinae; D004952:Esters; D016670:Gabexate / Q000031:analogs & derivatives*; D006146:Guanidines / Q000494:pharmacology*; D008297:Male; D008647:Mesocricetus; D009602:Nitrosamines / Q000633:toxicity*; D010179:Pancreas / Q000187:drug effects / Q000473:pathology*; D010190:Pancreatic Neoplasms / Q000139:chemically induced* / Q000473:pathology; D011377:Proglumide / Q000031:analogs & derivatives / Q000494:pharmacology; D012016:Reference Values; D014361:Trypsin Inhibitors / Q000494:pharmacology*
chemical_list: D002273:Carcinogens; D004952:Esters; D006146:Guanidines; D009602:Nitrosamines; D014361:Trypsin Inhibitors; C034532:camostat; D016670:Gabexate; C013622:nitrosobis(2-oxopropyl)amine; D002766:Cholecystokinin; D011377:Proglumide; C048181:lorglumide